SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.
David. R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.
A live webcast of the Jefferies presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.
ESSA Pharma, Inc.
Peter Virsik
Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.71 |
Daily Volume: | 80,483 |
Market Cap: | US$75.910M |
February 11, 2025 December 17, 2024 September 13, 2024 September 11, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load